IJR vs XBI
iShares Core S&P Small-Cap ETF vs SPDR S&P Biotech ETF
- • IJR has the lower expense ratio at 0.06% vs 0.35% for XBI.
- • IJR pays a higher dividend yield (1.16%).
Side-by-side metrics
| Metric | IJR | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.06% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.16% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $102.56B | $8.30B |
YTD return | 15.78% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.17 | 1.09 |
P/E ratio | 18.30 | — |
Last price | $137.64 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
IJR top holdings
| XTSLA | BlackRock Cash Funds Treasury SL Agency | 1.44% |
| VIAV | Viavi Solutions Inc | 0.72% |
| SANM | Sanmina Corp | 0.71% |
| FORM | FormFactor Inc | 0.63% |
| MOH | Molina Healthcare Inc | 0.60% |
| PRIM | Primoris Services Corp | 0.58% |
| SMTC | Semtech Corp | 0.58% |
| ESI | Element Solutions Inc | 0.58% |
| AGX | Argan Inc | 0.55% |
| VSAT | Viasat Inc | 0.53% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About IJR
IJR (iShares Core S&P Small-Cap ETF) is Tracks the S&P SmallCap 600 index. Managed by iShares, the fund carries $102.6B in assets under management, an expense ratio of 0.06%, a dividend yield of 1.16%. Its largest holding is BlackRock Cash Funds Treasury SL Agency (XTSLA), which represents 1.4% of the portfolio. Real Estate is the fund's largest sector exposure at 7.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.